Free Republic
Browse · Search
General/Chat
Topics · Post Article

To: firebrand; RaceBannon; sauropod

Notice at that link that there is a webinar tomorrow.


116 posted on 04/05/2020 3:07:46 PM PDT by firebrand
[ Post Reply | Private Reply | To 113 | View Replies ]


To: firebrand; PA Engineer; Mariner; Black Agnes

COVID-19 – A co-infection of SARS-CoV-2 and Prevotella genus bacteria

 

Thesis:

The COVID-19 disease is a synergistic co-infection of human lung tissue and a normal gram negative anaerobic bacterium, Prevotella.  SARS-CoV-2 can infect both human lung tissue and the Prevotella bacterium. The viral pneumonia setup by the SARS-CoV-2 in the alveolar sacs of the lower lung lowers the oxygen level and creates a favorable environment for the anaerobic Prevotello bacterium to flourish. High blood sugar feeds the Prevotella bacterial growth. The increase in bacteria provides a growth medium for SARS-CoV-2 to infect and replicate.

 

Course of Infection:

1.       Initial infection of SARS-CoV-2 is acquired via droplet or aerosol inhalation.

2.       Prevotella is present in the oral cavity an is aspirated into the lungs. Normally high oxygen levels limit growth as part of the microbiome of lower lung tissue.

3.       In the initial 12 hours after infection, the SARS-CoV-2 replicates in the lower lung and is subject to shedding in coughs, sneezes or ordinary conversation.

4.       During the “incubation” phase, SARS-CoV-2 is damaging the lower lung epithelium creation a low oxygen fluid. This fluid includes nutrients from the blood.

5.       The Prevotello bacteria present begin to multiply and their exotoxins begin damaging the lung tissue.  The patient becomes aware of tightness in the chest as the Prevotello infection takes hold. The febrile symptoms appear as the body tries to fight the infection.

Treatment Of COVID-19

Successful treatments in France revealed that use of hydroxychloroquine as a zinc ionophore to stop replication of SARS-CoV-2 in human cells AND azithromycin successfully treated the infection. Others have use high dose vitamin C to kill exogenous virus and Chaga mushroom extracts to leverage the 3CL protease inhibition to stop replication.  Measures applied early to halt the replication and kill the virus are satisfactory before the Prevotella pneumonia gets started. After that point, it is necessary to bring in the azithromycin to kill the Prevotella to halt that infection and eliminate the secondary reservoir of SARS-CoV-2.

 

References

https://www.researchgate.net/publication/339008515_The_2019_Wuhan_outbreak_is_caused_by_the_bacteria_Prevotella_which_is_aided_by_the_coronavirus_possibly_to_adhere_to_epithelial_cells_-_Prevotella_is_present_in_huge_amounts_in_patients_from_both_Chin

https://sanchakblog.wordpress.com/2020/02/06/one-has-to-be-blind-as-a-bat-forgive-the-irony-not-to-see-prevotella-in-this-si-table-by-chinese-authors-who-rna-seqed-the-wuhan-ncov-from-7-people/

 

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=2ahUKEwiis4zPpdLoAhW-HDQIHVkiA2UQFjACegQIBxAB&url=https%3A%2F%2Fosf.io%2Fdvc6k%2Fdownload&usg=AOvVaw3a6aCeLKFoPLBrXix-KBbe


119 posted on 04/05/2020 3:16:39 PM PDT by Myrddin
[ Post Reply | Private Reply | To 116 | View Replies ]

To: firebrand; Black Agnes; Vermont Lt; Mariner

https://threadreaderapp.com/thread/1246472870936666118.html

Coronavirus may be killed within 48 hours: “Amid a barrage of research on finding treatment for new coronavirus, Australian scientists have found that a common anti-parasitic drug killed SARS-CoV-2 virus, growing in cell culture, within 48 hours in lab settings.

then, check this out:
https://www.goodrx.com/ivermectin?dosage=3mg&form=tablet&label_override=ivermectin&quantity=10


137 posted on 04/05/2020 3:52:50 PM PDT by RaceBannon (Rom 5:8 But God commendeth his love toward us, in that, while we were yet sinners, Christ died for)
[ Post Reply | Private Reply | To 116 | View Replies ]

Free Republic
Browse · Search
General/Chat
Topics · Post Article


FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson